Answers are grounded in this paper and cite their sources.
Background Patients with chronic obstructive pulmonary disease (COPD) require long-term, multidisciplinary management. Still, multicenter programs often face fragmented data capture, delayed quality control, incomplete follow-up, and limited visibility of remote monitoring data. We developed a multicenter digital registry and management platform to support data acquisition, quality control, role-specific reporting, and wearable-device monitoring. Methods We conducted an observational implementation study of a digital COPD registry and management platform deployed in a multicenter project in China. The platform integrated electronic data capture (EDC) data, questionnaire and examination records, cohort and physician–patient management, daily COPD exacerbation recognition tool (CERT) symptom reporting, wearable-device monitoring, role-specific WeChat reports, and hierarchical dashboards. We synchronized data from cloud sources to a local adjunct management database and transformed them into management indicators. We evaluated registry and organizational coverage, CERT activity, current wearable-device binding, recent 30-day wearable-monitoring events and alerts, questionnaire-index coverage, and production WeChat messaging using verified production data available on 10 September 2026. Results The platform indexed 2,894 included participants across 18 regional subcenters and 114 participating units, with 347 physicians linked to at least one recruited participant. The CERT index contained 26,092 valid records, and 277 participants had current wearable-device bindings. During the most recent 30-day monitoring period, the platform recorded 44,879 blood-pressure events, 8,685 abnormal blood-pressure or heart-rate alerts, and 2,417 low-oxygen-saturation alerts (SpO 2 <90%). The questionnaire index contained 3,373 question-index entries, and production messaging logs recorded 9,144 successfully sent WeChat reports. Conclusions This multicenter COPD digital registry and management platform integrated heterogeneous source data into an operational registry, converted registry data into management indicators, and delivered those indicators through role-specific reporting and hierarchical dashboards. The verified 10 September 2026 snapshot demonstrated registry-scale implementation across participating centers, physicians, symptom monitoring, wearable monitoring, and production messaging. Further work should evaluate workflow impact, user adoption, and patient outcomes. Trial registration The parent IMPACT COPD Cohort (China) was prospectively registered at ClinicalTrials.gov (NCT07382986) on 3 February 2026.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: